iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
India’s MedTech growth is being driven by a combination of market expansion, public support for research and manufacturing, and potential AI applications in care. AI-enabled diagnostics are expected to be an early large-scale use, but that is a government knowledge paper’s forecast—not evidence that such systems are already widely adopted. The gap between promising pilots and routine care will depend on clinical evidence, usable health data, regulation, procurement and reimbursement.
How fast is India’s MedTech market growing?
India Brand Equity Foundation (IBEF), in a secondary-research summary dated 10 August 2026, estimates the country’s MedTech market at US$15–16 billion and reports annual growth of nearly 12%. IBEF also describes India as Asia’s fourth-largest MedTech market. These are attributed estimates, not a government census of device sales.
| Figure | What it represents | Source and qualification |
|---|---|---|
| US$11 billion in 2020 | Historical market baseline | Prime Minister’s Office, Government of India, in its 2023 policy announcement |
| US$15–16 billion | Estimated Indian MedTech market | IBEF secondary-research summary dated 10 August 2026 |
| Nearly 12% annually | Reported market growth rate | IBEF secondary-research summary dated 10 August 2026 |
| US$50 billion by 2030 | Government expectation announced with the 2023 policy | Not a confirmed outcome; the 2026 IBEF summary gives a broader US$30–50 billion projection range within the decade |
The figures are not interchangeable: one is a historical estimate, another a later secondary-research estimate, and the larger numbers are projections. They indicate the scale of the opportunity, but do not by themselves show how much growth is coming from AI, how many AI devices are in clinical use, or whether domestic manufacturers are capturing more value.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Where AI and next-generation technology could change care
A Department of Pharmaceuticals knowledge-paper summary released by the Press Information Bureau (PIB) on 8 August 2026 identifies diagnostics, clinical decision support, operational efficiency and medical-device innovation as areas where AI may contribute. It expects AI-enabled diagnostics to be the first large-scale MedTech application, potentially extending specialist expertise into primary and secondary care. That is an expectation, not a measured adoption result. The summary does not establish a directly comparable India-specific AI-MedTech market size or adoption rate.
AI-enabled diagnostics
Diagnostic systems can help analyze clinical information and flag findings for a clinician to review. The potential value in primary and secondary care is access to specialist capability where it is not readily available. A useful system must still perform adequately in the patient population and care setting where it is used; an encouraging pilot alone does not establish that it is safe or effective across other sites or groups.
Clinical decision support
AI decision-support tools can help clinicians interpret information or consider next steps. Their usefulness depends on how well the output fits the clinical workflow and whether clinicians can understand, assess and act on it. They support clinical work; their presence should not be treated as proof that a care decision can be automated or that outcomes have improved.
Operational efficiency and device innovation
The government summary also includes operational efficiency and innovation in medical devices among AI opportunity areas. These could involve making clinical or device workflows more effective, but the summary does not report adoption rates or quantified outcomes. Any claim of benefit needs evidence tied to the particular product and use.
Connected devices, software, robotics and remote diagnostics
IBEF’s 10 August 2026 secondary-research summary lists connected devices, software as a medical device, robotics and remote diagnostics as emerging opportunity categories. These categories point to possible directions for the sector; they do not establish that the technologies have scaled across Indian healthcare settings. For each product, the relevant questions are what it does, which patients and care level it serves, what evidence supports it, and how it fits into care and payment systems.
What is enabling the opportunity?
India brings digital infrastructure, software and engineering expertise, clinical diversity and growing manufacturing activity to the opportunity. Together, these can support development and testing of technologies for varied care settings. But capability to build software or run a pilot is only one part of deploying a medical product: providers also need reliable data, clinical validation, integration, regulatory clarity and a viable route to purchase and reimbursement.
The National Medical Devices Policy, 2023 sets out aims that include access, affordability, quality, patient-centred care, prevention, security, research and innovation, and skilled manpower. Its stated approaches include regulatory streamlining, medical-device parks and shared infrastructure, research and innovation hubs, private investment, workforce development and export promotion. These are policy objectives and proposed supports; their inclusion in the policy does not mean each has been fully implemented.
What public support has been reported as delivered?
Government-reported activity gives a more concrete view of implementation, though the figures refer to different dates and stages.
Free tools Windows power users keep installed
One-click scans. No signup required.
- Medical-device parks: A 2026 PIB update says parks are being developed in Greater Noida, Uttar Pradesh; Ujjain, Madhya Pradesh; and Kanchipuram, Tamil Nadu. As of December 2025, 199 manufacturers had been allotted land and 34 units had started plant construction. Land allotment and construction are progress measures, not proof that all facilities are operational or producing at scale.
- PRIP research support: The same update describes the Promotion of Research and Innovation in Pharma-MedTech (PRIP) scheme’s research and industry-academia components. As of November 2025, 111 research projects had been approved and seven Centres of Excellence were reported. Approval and centre counts show program activity, not completed products or clinical impact.
These programs matter because shared infrastructure, research links and manufacturing sites can help firms move from development toward production. Their eventual contribution to AI-enabled devices will depend on what is built, whether products meet clinical and regulatory requirements, and whether providers can adopt them.
Why manufacturing remains part of the AI story
The Technology Development Board (TDB) identifies AI-based devices for disease detection and monitoring among its medical-device development focus areas. Its “Advancing Technology and Innovation” page also says India remains 80–85% dependent on imports for complex and high-value medical devices. The page does not specify a publication date, so this should be read as TDB’s stated figure, not as a newly measured 2026 statistic.
TDB says domestic manufacturing has historically concentrated on consumables and disposables. That makes the opportunity more than adding AI software to care: it also includes building capacity in higher-value devices and the technologies around them. Import dependence is a constraint, while development support and parks are potential enablers; neither fact alone proves that the dependence is already falling.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Why successful pilots do not guarantee routine adoption
The Department of Pharmaceuticals’ 8 August 2026 summary identifies fragmented health data, limited evidence, evolving regulation, and limited reimbursement and procurement pathways as barriers to routine adoption. These obstacles explain why a promising demonstration may not translate into a standard clinical service.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problemsData and evidence must fit the intended use
Fragmented data can make it harder to develop, validate and connect AI systems. Evidence also needs to match the product’s intended patients and care setting. Results from one institution, population or pilot cannot automatically establish performance elsewhere. Providers need to know what the system was evaluated on, how it performs in relevant use, and how its output should affect care.
Regulation must address the product over time
Medical-device rules apply to products, not just to an algorithm in isolation. The government summary points to lifecycle-based regulation as an area needing attention, particularly as AI products evolve. For an adaptive system, users and regulators need clarity about how changes are assessed and controlled after initial validation. The summary identifies this need but does not set out a complete pathway for every AI product type.
Procurement and reimbursement must support deployment
A provider needs a way to buy, integrate and pay for a technology, and a sustainable reimbursement route may be necessary for routine use. Limited procurement and reimbursement pathways can leave a clinically promising tool confined to a funded pilot. The adoption case therefore includes cost and affordability for the health system and patient, not only technical performance.
Readiness is more than technical performance
Before judging a system ready for wider use, assess the full deployment:
- What clinical task does it perform, and is it intended for primary, secondary or another level of care?
- Was it validated in the patient population and setting where it will be used?
- Can it use the necessary health data and fit the provider’s existing workflow?
- How will the product be regulated throughout its lifecycle, including any changes to an AI system?
- Who can procure it, who pays, and is the route affordable and sustainable?
- Has it moved beyond a pilot into repeatable routine use?
What will show whether the growth is durable?
Market forecasts show possible scale; policy documents show direction; program updates show activity at specific dates. A stronger test is whether products demonstrate safe, relevant clinical value and become affordable, integrated tools that providers can procure and use consistently. For domestic industry, another test is whether support expands capability in complex, higher-value devices rather than only increasing activity at early development stages.
India has important ingredients for that shift, but they are not the same as completed adoption. The most informative progress will be evidence from intended care settings, functioning routes for regulation and payment, and reliable production—not projections or pilot announcements alone.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
